Sonoda; Junichiro

Patent Applications and Registrations

Patent applications and USPTO patent grants for Sonoda; Junichiro.The latest application filed is for "antibodies and methods of use".

Company Profile

8.10.17

Sonoda; Junichiro - South San Francisco CA
Sonoda; Junichiro - San Mateo CA
Sonoda; Junichiro - Lafayette CA

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Antibodies And Methods Of Use App 20220064331 - Chen; Yongmei ; et al.	2022-03-03
Fgfr1 Agonists And Methods Of Use App 20210087283 - Sonoda; Junichiro ; et al.	2021-03-25
Methods For Detecting And Quantifying Fgf21 App 20210025890 - Lowe; John Hok Nin ; et al.	2021-01-28
Host cell comprising nucleic acids encoding bispecific antibodies binding to beta-klotho and fibroblast growth factor receptor 1 and antibody production Grant 10,882,921 - Chen , et al. January 5, 2	2021-01-05
Fgfr1 Agonists And Methods Of Use App 20200140557 - Sonoda; Junichiro ; et al.	2020-05-07
Substrates Recognized By Fibroblast Activation Protein (fap) And Methods Of Using The Same App 20200055896 - BAINBRIDGE; Travis William ; et al.	2020-02-20
Antibodies And Methods Of Use App 20190177432 - Chen; Yongmei ; et al.	2019-06-13
Nucleic acids encoding bispecific antibodies binding to beta-Klotho and fibroblast growth factor receptor 1 Grant 10,246,518 - Chen , et al.	2019-04-02
Anti-FGFR2/3 antibodies and methods using same Grant 10,208,120 - Yin , et al. Feb	2019-02-19
Methods Of Screening For Multispecific Antibodies App 20190040142 - Dunshee; Diana Ronai ; et al.	2019-02-07
Antibodies And Methods Of Use App 20180105605 - Chen; Yongmei ; et al.	2018-04-19
Fgfr1 Agonists And Methods Of Use App 20180100018 - Sonoda; Junichiro ; et al.	2018-04-12
Chimeric Fibroblast Growth Factors With Altered Receptor Specificity App 20180079806 - SONODA; Junichiro	2018-03-22
Methods of treatment with bispecific antibodies binding to beta-klotho and fibroblast growth factor receptor 1 Grant 9,884,919 - Chen , et al. February 6, 2	2018-02-06
Bispecific antibodies binding to beta-klotho and fibroblast growth factor receptor 1 Grant 9,873,748 - Chen , et al. January 23, 2	2018-01-23
FGFR1 agonists and methods of use Grant 9,845,359 - Sonoda , et al. December 19, 2	2017-12-19
Antibodies And Methods Of Use App 20160319038 - CHEN; YONGMEI ; et al.	2016-11-03
Anti-fgfr2/3 Antibodies And Methods Using Same App 20160244525 - YIN; Yiyuan ; et al.	2016-08-25
Fgfr1 Agonists And Methods Of Use App 20150376283 - Sonoda; Junichiro ; et al.	2015-12-31
Antibodies And Methods Of Use App 20150218276 - Chen; Yongmei ; et al.	2015-08-06
FGFR1 agonists and methods of use Grant 9,085,626 - Sonoda , et al. July 21, 2	2015-07-21
Chimeric Fibroblast Growth Factors With Altered Receptor Specificity App 20140148388 - SONODA; Junichiro	2014-05-29
Chimeric fibroblast growth factors with altered receptor specificity Grant 8,535,912 - Sonoda September 17, 2	2013-09-17
Fgfr1 Agonists And Methods Of Use App 20120294861 - Sonoda; Junichiro ; et al.	2012-11-22
Chimeric Fibroblast Growth Factors With Altered Receptor Specificity App 20110104152 - SONODA; Junichiro	2011-05-05

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.